Compare PBI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBI | VIR |
|---|---|---|
| Founded | 1920 | 2016 |
| Country | United States | United States |
| Employees | 6600 | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2019 |
| Metric | PBI | VIR |
|---|---|---|
| Price | $10.87 | $8.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $11.67 | ★ $19.63 |
| AVG Volume (30 Days) | 2.7M | ★ 3.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,049.62 |
| P/E Ratio | $13.24 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.40 | $4.16 |
| 52 Week High | $13.11 | $10.91 |
| Indicator | PBI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 45.05 |
| Support Level | $9.78 | $5.14 |
| Resistance Level | $11.72 | $10.29 |
| Average True Range (ATR) | 0.34 | 0.47 |
| MACD | 0.07 | -0.18 |
| Stochastic Oscillator | 85.97 | 3.20 |
Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal work sharing discounts. It derives maximum revenue from SendTech Solutions.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.